Related News

• 2026/10/29

  2026 ESMO | Prof. Guiling Li: Enlonstobart plus chemotherapy induction followed by concurrent chemoradiotherapy for locally advanced cervical cancer demonstrates favorable efficacy and safety — deep tumor regression during induction enables radiotherapy dose reduction and field shrinking

• 2026/10/28

  2026 ESMO: First-in-Human Phase I/II Study Results of CSPC’s Innovative SYS6090 (JMT108) in Advanced Solid Tumors Presented

• 2026/10/09

  Phase I study results of monotherapy with SYS6002 (CSPC Innovation) for advanced cervical cancer presented as a rapid oral report at the 2026 International Gynecologic Cancer Society Global Annual Meeting

• 2026/09/15

  CSPC Innovation’s SYS6010 Presents Research Findings at the 2026 World Conference on Lung Cancer (WCLC)